Cargando…

Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project

Post-marketing surveillance is essential to evaluate the risk/benefit profile of drugs; however, pharmacovigilance studies comparing persistence and safety of biologic therapies in patients with inflammatory bowel disease (IBD) are scant. The aim of this study was to prospectively investigate persis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbieri, Maria Antonietta, Viola, Anna, Cicala, Giuseppe, Spina, Edoardo, Fries, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775949/ https://www.ncbi.nlm.nih.gov/pubmed/36552036 http://dx.doi.org/10.3390/biomedicines10123280

Ejemplares similares

Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
por: Barbieri, Maria Antonietta, et al.
Publicado: (2020)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2021)

Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease
por: Fries, Walter, et al.
Publicado: (2023)

Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents
por: Spina, Edoardo, et al.
Publicado: (2020)

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
por: Galletti, Cosimo, et al.
Publicado: (2023)

Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
por: Bellone, Federica, et al.
Publicado: (2023)

A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy
por: Belvedere, Alessandra, et al.
Publicado: (2021)

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study
por: Tallarico, Martina, et al.
Publicado: (2022)

Biologics, Pharmacovigilance, and Patient Safety: It’s All in the Name
por: Stevenson, James G., et al.
Publicado: (2016)

Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic
por: Viola, Anna, et al.
Publicado: (2021)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database
por: Russo, Giulia, et al.
Publicado: (2023)

Pharmacovigilance: Safety matters…
por: Biswas, Pipasha
Publicado: (2008)

Vitamin D and Inflammatory Bowel Disease
por: Ardesia, Marco, et al.
Publicado: (2015)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
por: Gozzo, Lucia, et al.
Publicado: (2017)

Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region
por: Gagliardi, Agnese, et al.
Publicado: (2022)

Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure
por: Shahid, Imran, et al.
Publicado: (2022)

The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project
por: Pal, Shanthi N., et al.
Publicado: (2015)

A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
por: Bioque, Miquel, et al.
Publicado: (2015)

Endoscopy in inflammatory bowel disease: from guidelines to real life
por: Negreanu, Lucian, et al.
Publicado: (2019)

Safety of biologics in inflammatory bowel disease patients with COVID-19
por: Weissman, Simcha, et al.
Publicado: (2021)

Big data, medicines safety and pharmacovigilance
por: Hussain, Rabia
Publicado: (2021)

Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study
por: Iannone, Luigi Francesco, et al.
Publicado: (2020)

Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers
por: Tursi, Antonio, et al.
Publicado: (2018)

Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2020)

Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study
por: Lo Giudice, Ivan, et al.
Publicado: (2019)

Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study
por: Cicala, Giuseppe, et al.
Publicado: (2020)

Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations
por: Chaudhary, Anand, et al.
Publicado: (2010)

International Society of Pharmacovigilance monitors vaccine safety
Publicado: (2022)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
por: Argüelles-Arias, F., et al.
Publicado: (2017)

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
por: Palleria, Caterina, et al.
Publicado: (2018)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ehqgsceajf14glh3vj7o4ofg9d